Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-11-06 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东工商登记事项变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding changes in the industrial and commercial registration details of a shareholder holding more than 5% of the company's shares. It details changes in the capital contributions and partnership shares of limited partners in a major shareholder entity, and clarifies that these changes do not affect the company's control or governance structure. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, as it concerns changes in significant share ownership levels or related shareholder structure information.
2020-11-06 Chinese
关于收到深圳证券交易所《关于深圳华大基因股份有限公司申请向特定对象发行股票的审核中心意见告知函》的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (632 characters) from Shenzhen BGI Co., Ltd. regarding receipt of a notification from the Shenzhen Stock Exchange about the company's application for a private placement of shares. It mentions the review process and next steps including registration with the China Securities Regulatory Commission. The document is an update on a capital raising process and does not contain financial statements or detailed financial data. It is not a full report but an announcement about financing activity. Therefore, it fits best under Capital/Financing Update (CAP).
2020-11-04 Chinese
关于放弃控股子公司股权优先购买权暨关联交易的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a related party transaction involving the waiver of the preemptive rights to purchase equity in a controlling subsidiary. It details the completion of the equity transfer and the subsequent business registration changes, including updated shareholder structure and issuance of a new business license. The document references prior announcements and resolutions but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a corporate transaction and related administrative updates rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-04 Chinese
向特定对象发行股票募集说明书（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to "Prospectus" or "Offering Circular" for a specific stock issuance to particular investors. It details the issuance of shares to specific investors, the number of shares, pricing, use of proceeds, approvals obtained and pending, risk factors, and other related information. It includes detailed sections on the issuance background, pricing, shareholding structure, risk disclosures, and approvals. This is a comprehensive document related to a capital raising event through a private placement or targeted share issuance. It is not an earnings release, annual report, or management discussion, nor is it a simple announcement or regulatory filing. It is a detailed capital/financing update document describing a specific stock issuance and fundraising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the full report, not just an announcement or summary.
2020-11-03 Chinese
关于公司申请向特定对象发行股票的审核问询函的回复（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry regarding a company's application for a specific stock issuance to targeted investors. It includes extensive descriptions of investment projects, capital expenditure breakdowns, and strategic business plans related to the issuance. The content focuses on the company's capital raising activities, project funding, and investment use, which aligns with updates on financing activities or capital structure changes. There is no indication that this is an annual report, earnings release, or other financial statement. The document is not a simple announcement but a detailed reply to a regulatory inquiry about a capital raising event. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2020-11-03 Chinese
中信证券股份有限公司关于公司对参股公司增资暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s capital increase in an associate company and related party transactions. It includes comprehensive information about the transaction, the involved parties, financial data of the target company, legal and regulatory compliance, board and independent directors' opinions, and the sponsor's verification opinion. The document is lengthy (over 11,000 characters) and contains substantive content about the transaction and its implications, not merely an announcement or certification. It is not a full annual or interim financial report, nor a call transcript or earnings release. The content focuses on a capital increase and related party transaction, which fits the category of Capital/Financing Update (CAP).
2020-10-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.